RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

Stock Information for Redhill Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Redhill Biopharma Ltd.

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.